These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25232263)

  • 1. Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.
    Chmielewska-Wilkoń D; Reggiardo G; Egan CG
    World J Gastroenterol; 2014 Sep; 20(34):12283-91. PubMed ID: 25232263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.
    Clavé P; Acalovschi M; Triantafillidis JK; Uspensky YP; Kalayci C; Shee V; Tack J;
    Aliment Pharmacol Ther; 2011 Aug; 34(4):432-42. PubMed ID: 21679214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP; Lam C; Mehta S; Spiller RC
    Trials; 2013 Jan; 14():10. PubMed ID: 23302220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome.
    Glende M; Morselli-Labate AM; Battaglia G; Evangelista S
    Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1331-8. PubMed ID: 12468954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial.
    Kim JI; Kim P; Lee JH; Kim YJ; Yang NR; Baeg MK; Choi JS; Kim HJ; Kim J; Sunwoo YY; Lee JH; Ha H; Park TY
    BMJ Open; 2017 Dec; 7(11):e018362. PubMed ID: 29196484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
    Kemppinen A; Howell C; Allgar V; Dodd M; Gregson J; Knowles C; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Trials; 2020 Jan; 21(1):122. PubMed ID: 32000822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
    Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
    Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
    Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
    Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial.
    Pace F; Maurano A; Ciacci C; Savarino V; Attili A; Iaquinto G; Magni E; Porro GB
    Eur Rev Med Pharmacol Sci; 2010 Mar; 14(3):155-62. PubMed ID: 20391952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
    Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
    Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Cayzeele-Decherf A; Pélerin F; Leuillet S; Douillard B; Housez B; Cazaubiel M; Jacobson GK; Jüsten P; Desreumaux P
    World J Gastroenterol; 2017 Jan; 23(2):336-344. PubMed ID: 28127207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial.
    Plasse TF; Barton G; Davidson E; Abramson D; Kalfus I; Fathi R; Raday G; Harris MS
    Am J Gastroenterol; 2020 Sep; 115(9):1466-1473. PubMed ID: 32639235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo.
    Lyra A; Hillilä M; Huttunen T; Männikkö S; Taalikka M; Tennilä J; Tarpila A; Lahtinen S; Ouwehand AC; Veijola L
    World J Gastroenterol; 2016 Dec; 22(48):10631-10642. PubMed ID: 28082816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partially hydrolyzed guar gum in pediatric functional abdominal pain.
    Romano C; Comito D; Famiani A; Calamarà S; Loddo I
    World J Gastroenterol; 2013 Jan; 19(2):235-40. PubMed ID: 23345946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.
    Anderle K; Wolzt M; Moser G; Keip B; Peter J; Meisslitzer C; Gouya G; Freissmuth M; Tschegg C
    World J Gastroenterol; 2022 Dec; 28(46):6573-6588. PubMed ID: 36569277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irritable bowel syndrome: focus on otilonium bromide.
    Boeckxstaens G; Clavé P; Corazziari ES; Tack J
    Expert Rev Gastroenterol Hepatol; 2014 Feb; 8(2):131-7. PubMed ID: 24417261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
    Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
    Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.